How transcription factor mutations shape diabetes risk
Diabetes affects hundreds of millions of people worldwide. The disease features elevated blood glucose levels and disrupted fat and protein metabolism. The musculoaponeurotic fibrosarcoma, or MAF, family of transcription factors regulate various processes in tissue development, including hormone production in pancreatic islet cells. Within this family, MAFA and MAFB are essential for development and maturation of insulin- and glucagon-producing cells.
Previous research showed that MAFA and MAFB expression is affected in diabetes, both Type 1 and Type 2. In addition, a mutation in MAFA that prevents phosphorylation of a key serine residue causes monogenic diabetes. Mutation of the equivalent residue in MAFB leads to a pediatric multisystem disorder. In a recent Journal of Biological Chemistry , Jeeyeon Cha, Xin Tong and Katie Coate from Vanderbilt University and collaborators in the U.S. examined how mutations in conserved DNA-binding domains of the MAF proteins impact their regulation of the insulin gene. The authors used targeted mutagenesis and artificial intelligence structure prediction using AlphaFold 2 for their analysis.
They found one MAFA variant, with a mutation in the conserved DNA-binding region, that exhibited normal activity. The equivalent mutation in MAFB did not retain normal activity. Therefore, the researchers searched for structural differences between the MAFA and MAFB proteins outside of the DNA-binding region that might also contribute to its activity. Their AlphaFold 2 models showed that the two proteins differed in the C-terminal domains. The researchers created chimeras by exchanging the two C-terminal domains of MAFA and MAFB, which changed how each protein regulated the insulin gene. These results help clarify differences between MAFA and MAFB, which of their domains affect activity and possible ways that they contribute to different disease states.
Future studies will focus on regions of MAFA and MAFB that may interact with other coregulators of the insulin gene.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7鈥�10, in Maryland.
Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-尾 signaling and promotes colorectal cancer.
Mapping fentanyl鈥檚 cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl鈥檚 effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.
Designing life鈥檚 building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.
Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.
How lipid metabolism shapes sperm development
Researchers at Hokkaido University identify the enzyme behind a key lipid in sperm development. The findings reveal how seminolipids shape sperm formation and may inform future diagnostics and treatments for male infertility.